Ratings Remedy Entertainment Oyj

Equities

REMEDY

FI4000251897

Delayed Nasdaq Helsinki 07:13:18 2024-05-21 am EDT 5-day change 1st Jan Change
19.32 EUR -3.40% Intraday chart for Remedy Entertainment Oyj +0.52% -23.94%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Software

1st Jan change Capi. Investor Rating ESG Refinitiv
-23.94% 294M -
+13.11% 3,161B
C+
+11.55% 87.62B
B
+7.38% 79.59B
B+
-13.48% 54.14B
B+
+25.92% 48.15B
D+
-24.39% 46.81B
B-
+35.49% 47.69B
D+
+80.54% 42B
D+
-6.24% 25.77B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. REMEDY Stock
  4. Ratings Remedy Entertainment Oyj
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW